Table 3b.
Prevalence | Sensitivity | 95% CI |
Specificity | 95% CI |
LR+ | LR− | |||
---|---|---|---|---|---|---|---|---|---|
LL | UL | LL | UL | ||||||
AHI4%, no./ h | |||||||||
≥5 | 0.53 | 0.87 | 0.71 | 0.95 | 0.79 | 0.62 | 0.91 | 4.22 | 0.17 |
≥10 | 0.33 | 0.88 | 0.66 | 0.97 | 0.83 | 0.69 | 0.92 | 5.25 | 0.15 |
≥15 | 0.31 | 0.68 | 0.45 | 0.85 | 0.90 | 0.77 | 0.96 | 6.82 | 0.35 |
RDI, no./h | |||||||||
≥10 | 0.71 | 0.82 | 0.69 | 0.91 | 0.90 | 0.68 | 0.98 | 8.65 | 0.20 |
≥15 | 0.54 | 0.82 | 0.66 | 0.92 | 0.91 | 0.75 | 0.98 | 9.03 | 0.20 |